NCT02390297Active, not recruiting
Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
Long term safety follow-up of Cal-1 recipients
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 11 (actual)
- First submitted
- 11 Mar 2015
- Start date
- Apr 2015
- Primary completion date
- Oct 2031
- Lead sponsor
- Calimmune, Inc.
- Diseases
- HIV
- NCT number
- NCT02390297
What you commit to
- Study type: Observational
- Participants enrolled: 11
- From Apr 2015 to the primary completion date, Oct 2031
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to understand and provide informed consent
Who the study is looking for
- Signed informed consent
- Previous treatment with the Cal-1 modified hematopoietic cellular products
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA CARE Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Quest Clinical Research Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.